MCM
VYGR icon

Matarin Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Matarin Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-21,554
Closed -$301K – 244
2019
Q4 		$301K Sell
21,554
-1,149
-5% -$16.7K 0.03% 231
2019
Q3 		$391K Buy
+22,703
New +$477K 0.03% 234

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Matarin Capital Management's VYGR Position: Q1 2020 in Review

Matarin Capital Management sold out of Voyager Therapeutics (VYGR) in Q1 2020, closing a stake of 21,554 shares — an estimated $301K sold.

Matarin Capital Management first reported a position in VYGR in Q3 2019 and held it in 2 quarters. The position peaked at $391K in Q3 2019. 121 funds tracked by Wall St. Rank hold VYGR as of Q1 2020.

  • Matarin Capital Management reported no remaining Voyager Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Matarin Capital Management sold 21,554 Voyager Therapeutics shares in Q1 2020, an estimated $301K.
  • Matarin Capital Management first reported a position in Voyager Therapeutics in Q3 2019 and held it in 2 quarters.
  • Matarin Capital Management's Voyager Therapeutics position peaked at $391K in Q3 2019.
  • 121 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2020.

Based on Matarin Capital Management's 13F filing for Q1 2020, filed 27 Apr 2020.